Ohio State University B-Vaxx Report, page-29

I don't think they are terrible(there are respondents and disease is stabilized well). There is good evidence in patients who showed anti tumor activity and no dose limitations/safety issues. However trail being limited to one center and there is still room for better selection of patients(the group is very heterogeneous) and they were heavily pre-treated and proper randomization is lacking. I believe with more centers and better clinical trail design and measurement, it will probably have more promising results.

The reason I am buying huge shares of IMU is the the diversity of pipeline and amazing researchers. More over I like the B cell concept to be innovative.